Bispecific antibodies and their applications

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Fan, Gaowei ^a,b   Wang, Zujian ^c   Hao, Mingju ^a,b   Li, Jinming ^a,b  

^a BEIJING HOSPITAL   (China)

^b GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^c Shunyi Maternal and Child Health Care Hospital   (China)

Author keywords

Bispecific antibody; BiTE; Cancer; Catumaxomab; Diagnosis; Formats

Indexed keywords

AMG 330; BAY 2010112; BISPECIFIC ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; COVA 322; ERTUMAXOMAB; ES 414; FBTA 05; LY 3164530; MDX 447; MEDI 565; MGD 006; MGD 007; MGD 010; MM 111; MM 141; MOR 209; MSB 0010841; MT 111; MT 112; REGN 1979; RG 7716; RG 7802; RG 7813; RO 6895882; SOLITOMAB; TF 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANUCIZUMAB; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIBODY DETECTION; ANTIBODY PRODUCTION; B CELL LEUKEMIA; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; BREAST CANCER; BREAST TUMOR; CARCINOGENESIS; CARCINOMATOUS PERITONITIS; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; GASTROINTESTINAL CARCINOMA; HALF LIFE TIME; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; MALIGNANT ASCITES; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE PERMEABILITY; NATURAL KILLER CELL; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE TUMOR; PSORIASIS; PSORIASIS VULGARIS; REVIEW; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH ADENOCARCINOMA; THYROID MEDULLARY CARCINOMA; WET MACULAR DEGENERATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; T LYMPHOCYTE; VASCULARIZATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES;

EID: 84950989868     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0227-0     Document Type: Review

References (83)

1. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7(1):9-14.
2. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58.
3. Kontermann R. Dual targeting strategies with bispecific antibodies. mAbs. 2012;4(2):182-97.
4. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000-10.
5. Dhimolea E, Reichert JM. World bispecific antibody summit, September 27-28, 2011, Boston, MA. mAbs. 2012;4(1):4-13.
6. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2):95-106.
7. Chames P, Baty D. Bispecific antibodies for cancer therapy. mAbs. 2009;1(6):539-47.
8. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838-47.
9. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36(6):458-67.
10. Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, et al. Knobs-intoholes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs. 2013;5(6):872-81.
11. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16(7):677-81.
12. Onitsuka M, Kawaguchi A, Asano R, Kumagai I, Honda K, Ohtake H, et al. Glycosylation analysis of an aggregated antibody produced by Chinese hamster ovary cells in bioreactor culture. J Biosci Bioeng. 2014;117(5):639-44.
13. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci. 2011;108(27):11187-92.
14. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res. 2013;19(24):6730-40.
15. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol. 2014;32(2):191-8.
16. Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules. mAbs. 2009;1(4):339-47.
17. TM) technology: a versatile, novel format for the next generation of dual-targeting biologics. In: Kontermann RE, editor. Bispecific Antibodies. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 171-85.
18. Eigenbrot C, Fuh G. Two-in-one antibodies with dual action Fabs. Curr Opin Chem Biol. 2013;17(3):400-5.
19. Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ETJ, van Kampen MD, et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc. 2014;9(10):2450-63.
20. Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. 2015;6:6113.
21. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 1999;453(1-2):164-8.
22. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011;117(17):4542-51.
23. Garber K. Bispecific antibodies rise again. Nat Rev Drug Discov. 2014;13(11):799-801.
24. Revets H, Baetselier PD, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005;5(1):111-24.
25. Conrath KE, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in Bispecific and bivalent antibody constructs. J Biol Chem. 2001;276(10):7346-50.
26. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang C-H. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49(1):158-63.
27. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868-76.
28. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167-83.
29. Merlot AM, Kalinowski DS, Kovacevic Z, Jansson PJ, Lane DJ, Huang ML-H, et al. Making a case for albumin-a highly promising drug-delivery system. Future Med Chem. 2015;7(5):553-6.
30. Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, et al. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells. J Hematol Oncol. 2015;8(1):18.
31. Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol. 2013;9(4):527-39.
32. Zugmaier G, Klinger M, Schmidt M, Subklewe M. Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015;67(2):58-66.
33. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a singlestep purification of bispecific antibodies. J Immunol. 1995;155(1):219-25.
34. Hirschhaeuser F, Leidig T, Rodday B, Lindemann C, Mueller-Klieser W. Test system for trifunctional antibodies in 3D MCTS culture. J Biomol Screen. 2009;14(8):980-90.
35. Weidle UH, Kontermann RE, Brinkmann U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol. 2014;41(5):653-60.
36. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 2009;69(10):4270-6.
37. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(10):3085-91.
38. Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer. 2008;123(5):1181-9.
39. Breton CS, Nahimana A, Aubry D, Macoin J, Moretti P, Bertschinger M, et al. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol. 2014;7(1):33.
40. Mullard A. FDA approves first bispecific. Nat Rev Drug Discov. 2014;14(1):7.
41. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334-42.
42. Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):111.
43. Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8(1):111.
44. Tang J, Shen D, Zhang J, Ligler FS, Cheng K. Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done. Expert Opin Biol Ther. 2015;15(9):1251-5.
45. Rader C. DARTs take aim at BiTEs. Blood. 2011;117(17):4403-4.
46. Uy G, Stewart S, Baughman J, Rettig M, Chichili G, Bonvini E, et al. A phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014;2 Suppl 3:87.
47. Moore PA, Alderson R, Shah K, Yang Y, Burke S, Li H, et al. Abstract 669: development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer. Cancer Res. 2014;74 Suppl 19:669.
48. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth C-W, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol. 1999;293(1):41-56.
49. Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8(1):96.
50. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5):361-70.
51. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 Oncogenic unit and inhibits Heregulin-induced activation of ErbB3. Mol Cancer Ther. 2012;11(3):582-93.
52. Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014;13(2):410-25.
53. Cole P. Duligotuzumab. Human anti-EGFR/anti-HER3 MAb, colorectal cancer therapy, head and neck cancer therapy. Drugs Future. 2015;40(3):167.
54. Fayette J, Wirth LJ, Oprean C, Hitt R, Udrea A, Jimeno A, et al. Randomized phase II study of Mehd7945a (mehd) vs cetuximab (cet) in > = 2nd-line recurrent/metastatic squamous cell carcinoma of the head & neck (rmscchn) progressive on/after platinum-based chemotherapy (ptct). Ann Oncol. 2014;25 suppl 4:iv340.
55. Clement PM, Machiels JP, Wirth L, Specenier P, Seiwert T, Mardjuadi F, et al. 989pdphase 1b study of MEHD7945A (mehd) Plus Cisplatin/Fluorouracil (cis/5fu) or Carboplatin/Paclitaxel (carbo/Pac) for 1st-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (rmscchn). Ann Oncol. 2014;25(suppl 4):iv341-iv341.
56. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2(2):83-90.
57. Biel NM, Siemann DW. Targeting the angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett. doi:10.1016/j.canlet.2014.09.035
58. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280-309.
59. Schett G, Elewaut D, McInnes IB, Dayer J-M, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19(7):822-4.
60. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(5):125-39.
61. Baeten DLP, Kuchroo VK. How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013;19(7):824-5.
62. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13(10):925-31.
63. Bossaller L, Rothe A. Monoclonal antibody treatments for rheumatoid arthritis. Expert Opin Biol Ther. 2013;13(9):1257-72.
64. Williams SC. Small nanobody drugs win big backing from pharma. Nat Med. 2013;19(11):1355-6.
65. Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, et al. The coming of age of engineered multivalent antibodies. Drug Discov Today. 2015;20(5):588-94.
66. Ekerljung L, Bass T, Wållberg H, Sohrabian A, Anderson K, Friedman M, et al. Bispecific affibody molecules for targeting of EGFR and HER2. mAbs. 2012; 4(1):14-6.
67. Kingwell K. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs. Nat Rev Drug Discov. 2014;13(7):483-4.
68. McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA, Laverman P, et al. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50(6):991-8.
69. Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci. 2011;108(20):8194-9.
70. Taylor K. Engineering bispecific antibodies for targeted delivery of cytotoxin-loaded nanoparticles to tumour cells. The Australian Institute for Bioengineering and Nanotechnology, University of Queensland. 2015. doi: 10.14264/uql.2015.802.
71. Schoffelen R, Boerman O, Van Der GW, Van HC, Sharkey R, McBride W, et al. Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): first results. J Nucl Med. 2011;52 suppl 1:358.
72. Stanimirovic D, Kemmerich K, Haqqani AS, Farrington GK: Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. Adv Pharmacol. 2014;71:301-335.
73. Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013;5(183):183ra57.
74. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med. 2011;3(84):84ra43.
75. Hannah Byrne PJC. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013;31:11.
76. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983;305(5934):537-40.
77. Suresh MR, Cuello AC, Milstein C. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc Natl Acad Sci. 1986;83(20):7989-93.
78. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, et al. A multifunctional bispecific antibody protects against pseudomonas aeruginosa. Sci Transl Med. 2014;6(262):262ra155.
79. Kingwell K. Infectious diseases: two-hit antibody tackles bacteria. Nat Rev Drug Discov. 2015;14(1):15.
80. Berg J, Lötscher E, Steimer KS, Capon DJ, Baenziger J, Jäck HM, et al. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc Natl Acad Sci. 1991;88(11):4723-7.
81. Park SS, Ryu CJ, Kang YJ, Kashmiri SVS, Hong HJ. Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens. Mol Immunol. 2000;37(18):1123-30.
82. Taylor RP, Martin EN, Reinagel ML, Nardin A, Craig M, Choice Q, et al. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol. 1997;159(8):4035-44.
83. Fan D, Li W, Yang Y, Zhang X, Zhang Q, Yan Y, et al. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patientderived B-ALL cells. J Hematol Oncol. 2015;8(1):108.